Showing 121 - 134 results of 134 for search '"natural killer cell"', query time: 0.08s Refine Results
  1. 121

    Mesenchymal Stem Cells Carrying Viral Fusogenic Protein p14 to Treat Solid Tumors by Inducing Cell–Cell Fusion and Immune Activation by Yao Wang, Xunlei Pang, Ruirui Li, Jiuzhou Chen, Chen Wen, Huihuang Zhu, Tingyu Long, Jianjie Li, Lijun Zheng, Youcai Deng, Junnian Zheng, Bo Xu

    Published 2025-01-01
    “…In mouse tumor models, mMSCs-p14 treatment markedly suppressed tumor growth and also enhanced the activity of natural killer cells and macrophages. Controllability and safety of MSCs-p14 therapy were further improved by introducing the tetracycline-controlled transcriptional system. …”
    Get full text
    Article
  2. 122

    Screening of necroptosis-related genes and evaluating the prognostic capacity, clinical value, and the effect of their copy number variations in acute myeloid leukemia by Dake Wen, Ru Yan, Lin Zhang, Haoyang Zhang, Xuyang Chen, Jian Zhou

    Published 2025-01-01
    “…The ssGSEA result showed the expression of RAPR1 was inversely related to CD56dim natural killer cells and the expression of CTSS was positive related to Myeloid-derived suppressor cells (MDSCs) in AML. …”
    Get full text
    Article
  3. 123

    Association of ERAP1 and ERAP2 gene polymorphisms and ERAP2 protein with the susceptibility and severity of rheumatoid arthritis in the Ukrainian population by Iryna Kril, Iryna Kril, Andrzej Wiśniewski, Agnieszka Tarnowska, Khrystyna Lishchuk-Yakymovych, Yaryna Bojko, Piotr Kuśnierczyk, Valentyna V. Chopyak, Izabela Nowak

    Published 2025-01-01
    “…These molecules present antigenic peptides to CD8+ T lymphocytes and natural killer cells. HLA-I molecules bind their peptide cargo (8–10 amino acids long) in the endoplasmic reticulum. …”
    Get full text
    Article
  4. 124

    First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies by Peter Ellmark, Jeffrey Yachnin, Ana Carneiro, Lena Schultz, Amanda Hahn, Sumeet Ambarkhane, Karin Enell Smith, Gustav J. Ullenhag

    Published 2025-01-01
    “…ATOR-1017 activates T cells and natural killer cells in the tumor environment, leading to immune-mediated tumor cell death.Methods In this first-in-human, multicenter, phase I study, ATOR-1017 was administered intravenously every 21 days as a monotherapy to patients with advanced, unresectable solid tumors having received multiple standard-of-care treatments. …”
    Get full text
    Article
  5. 125

    Role of Fcγ receptors in HER2-targeted breast cancer therapy by Hope S Rugo, Antonino Musolino, William J Gradishar, Jeffrey L Nordstrom, Edwin P Rock, Fernanda Arnaldez, Mark D Pegram

    Published 2022-01-01
    “…Activating FcγRIIIa (CD16A) on natural killer cells plays a crucial role in mediating ADCC, and activating FcγRIIa (CD32A) and FcγRIIIa on macrophages are important for mediating ADCP. …”
    Get full text
    Article
  6. 126

    INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses by Jason Ho, Chelsie Macedo, Garrett Cyprus, Rajay Pandit, Anya Polovina, Nadja Kern, Abrahim Hussain, Sae Jeong Ahn, William Crago, Emily Rowell, Florian J Sulzmaier, John C Timmer, Brendan P Eckelman

    Published 2023-01-01
    “…Preclinical safety, as well as pharmacodynamic (PD) and PK profiling was carried out in non-human primates.Results INBRX-120 effectively expanded and enhanced the cytotoxic capacity of CD8 T cells and natural killer cells towards tumor cells without affecting regulatory T cells in vitro and in vivo. …”
    Get full text
    Article
  7. 127

    Immune regulatory genes impact the hot/cold tumor microenvironment, affecting cancer treatment and patient outcomes by Mengmeng Sang, Jia Ge, Juan Ge, Juan Ge, Gu Tang, Qiwen Wang, Jiarun Wu, Liming Mao, Liming Mao, Xiaoling Ding, Xiaorong Zhou

    Published 2025-01-01
    “…For validation, a clinical cohort of patients diagnosed with pancreatic adenocarcinoma was examined using multiplex immunohistochemistry.ResultsWe were able to differentiate between hot and cold tumors in various types of cancer (bladder urothelial carcinoma, pancreatic adenocarcinoma, and cervical squamous cell carcinoma) by analyzing the presence of CD8+ T cells, activated natural killer cells, and M2-type macrophages, as well as the cytolytic activity and T cell proliferation. …”
    Get full text
    Article
  8. 128

    T lymphocytes induce human cancer cells derived from solid malignant tumors to secrete galectin-9 which facilitates immunosuppression in cooperation with other immune checkpoint pr... by Stephanie Schlichtner, Inna M Yasinska, Gurprit S Lall, Steffen M Berger, Sabrina Ruggiero, Dietmar Cholewa, Nijas Aliu, Bernhard F Gibbs, Elizaveta Fasler-Kan, Vadim V Sumbayev

    Published 2023-01-01
    “…Background Galectin-9 is a member of the family of lectin proteins and crucially regulates human immune responses, particularly because of its ability to suppress the anticancer activities of T lymphocytes and natural killer cells. Recent evidence demonstrated that galectin-9 is highly expressed in a wide range of human malignancies including the most aggressive tumors, such as high-grade glioblastomas and pancreatic ductal adenocarcinomas, as well as common malignancies such as breast, lung and colorectal cancers. …”
    Get full text
    Article
  9. 129

    Single-cell profiling transcriptomic reveals cellular heterogeneity and cellular crosstalk in breast cancer lymphatic node, bone, and brain metastases by Longyu Zhu, Miaomiao Liu, Yuguang Shang, Jingge Cheng, Hongye Zhao, Jun Zhang, Dongxing Shen

    Published 2025-01-01
    “…We identified five T cells (T memory, CD8 + T cells, regulatory T cells, natural killer cells, CD4 + T cells), three B cells (naïve B cells, memory B cells, plasma B cells), and five cancer-associated fibroblasts (CAFs) subpopulations (Smooth muscle cells (SMC), pericyte, antigen-presenting CAFs (apCAFs), proliferative CAFs (pCAFs), and matrix CAFs (mCAFs)). …”
    Get full text
    Article
  10. 130

    Sex and outcomes of patients with microsatellite instability-high and BRAF V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors by Michael Hoffmeister, Hermann Brenner, Chiara Cremolini, Sara Lonardi, Filippo Pietrantonio, Julien Taieb, David Tougeron, Robyn L Ward, Marco Vitellaro, Thierry André, Pierre Laurent-Puig, Jitendra Jonnagaddala, Francesca Bergamo, Raghav Sundar, Claire Gallois, Michael J Overman, Jakob Nikolas Kather, Lisa Salvatore, Romain Cohen, Rossana Intini, Priya Jayachandran, Miriam Koopman, Javier Ros, Marwan Fakih, Vincenzo Nasca, Giacomo Mazzoli, Jeanine M L Roodhart, Filippo Ghelardi, Elena Elez, Durgesh Wankhede, Marta Ligero, Joseph Zhao, Koen Zwart, Jeroen Derksen, Nicholas Hawkins, Javier Carmona

    Published 2025-02-01
    “…Exploratory transcriptomic analyses suggest that tumors of males with BRAF mutated MSI-H metastatic CRC are characterized by an enrichment of androgen receptor signature and an immune-depleted microenvironment, with a reduction in memory B cells, activated natural killer cells, and activated myeloid dendritic cells.Conclusions Overall, our findings suggest a complex interplay between sex and BRAF mutational status that may modulate the activity of ICIs in patients with MSI-H mCRC and pave the way to novel tailored strategies.…”
    Get full text
    Article
  11. 131

    High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis by Sehhoon Park, Jaeyun Jung, You Jeong Heo

    Published 2023-04-01
    “…Among the TMB-H patients, those who responded to anti-PD-L1 therapy had numerous active immune cells that infiltrated the tumor regions during the DSP analysis. Natural killer cells (p=0.04), cytotoxic T cells (p<0.01), memory T cells (p<0.01), naïve memory T cells (p<0.01), and proteins related to T-cell proliferation (p<0.01) were observed in a responder group compared with a non-responder group. …”
    Get full text
    Article
  12. 132

    Physiology and Pathophysiology of Marathon Running: A narrative Review by Lorin Braschler, Pantelis T. Nikolaidis, Mabliny Thuany, Daniela Chlíbková, Thomas Rosemann, Katja Weiss, Matthias Wilhelm, Beat Knechtle

    Published 2025-01-01
    “…It further positively affects hematopoiesis and cytotoxic abilities of natural killer cells, and may act neuroprotective on a long-term basis. …”
    Get full text
    Article
  13. 133

    GrB-Fc-KS49, an anti-EMP2 granzyme B fusion protein therapeutic alters immune cell infiltration and suppresses breast cancer growth by Ana Alvarez de Cienfuegos, Lawrence H Cheung, Khalid A Mohamedali, Michael G Rosenblum, Brian Aguirre, Cheng-Hsiang Lu, Anubhav Chandla, Nidhi Kejriwal, Lucia Liu, Ann M Chan, SuYin Kok, Sergio Duarte, David Casero, Madhuri Wadehra

    Published 2024-12-01
    “…Background Granzyme B (GrB) is a key effector molecule, delivered by cytotoxic T lymphocytes and natural killer cells during immune surveillance to induce cell death. …”
    Get full text
    Article
  14. 134